» Articles » PMID: 20353273

Transcriptional Inactivation of Secreted Frizzled-related Protein 1 by Promoter Hypermethylation As a Potential Biomarker for Non-small Cell Lung Cancer

Overview
Journal Neoplasma
Specialty Oncology
Date 2010 Apr 1
PMID 20353273
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Epigenetic silencing of secreted frizzled-related protein (SFRP) genes, antagonists of the WNT pathway, contributes to the pathogenesis of several cancers including non-small cell lung cancer (NSCLC). We hypothesize that methylation analysis of SFRPs family could improve their use as a panel of biomarkers for diagnosing and staging of NSCLC in China. The expression of four SFRP members (SFRP1, 2, 4, and 5) in NSCLC samples was screened by RT-PCR and quantitative real-time PCR. Only SFRP1 was significantly downregulated in NSCLC, as compared to adjacent normal tissues and benign pulmonary disease tissues (P=0.006). Promoter hypermethylation of SFRP1 was found in 32.1% (25/78) NSCLC specimens and was closely correlated with loss of expression, besides SFRP1 hypermethylation was associated with lymph metastasis (P=0.039) and disease progression within one year (P=0.027). Furthermore, methylated SFRP1 was detected in 28.2% (22/78) of plasma samples from NSCLC patients while only 4% (2/50) in cancer-free controls, and the concordance of SFRP1 methylation status in tumor tissues and corresponding plasmas was satisfactory (P <0.001). In conclusion, epigenetic inactivation of SFRP1 is a common event contributing to lung carcinogenesis and maybe used as a potential biomarker for NSCLC in Chinese population.

Citing Articles

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis.

Borg M, Wen S, Andersen R, Timm S, Hansen T, Hilberg O Cancers (Basel). 2023; 15(15).

PMID: 37568774 PMC: 10417522. DOI: 10.3390/cancers15153959.


Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.

Janin M, Davalos V, Esteller M Cancer Metastasis Rev. 2023; 42(4):1071-1112.

PMID: 37369946 PMC: 10713773. DOI: 10.1007/s10555-023-10120-3.


Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer.

Yang S, Huang Y, Zhao Q Front Immunol. 2022; 13:878740.

PMID: 35514980 PMC: 9066637. DOI: 10.3389/fimmu.2022.878740.


DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types.

Constancio V, Nunes S, Henrique R, Jeronimo C Cells. 2020; 9(3).

PMID: 32150897 PMC: 7140532. DOI: 10.3390/cells9030624.


Epigenetics of : The Dual Roles in Human Cancers.

Baharudin R, Tieng F, Lee L, Ab Mutalib N Cancers (Basel). 2020; 12(2).

PMID: 32074995 PMC: 7072595. DOI: 10.3390/cancers12020445.